Shares in Danish pharmaceutical giant Novo Nordisk surged on Wednesday after the company announced that sales of its new weight loss pill, Wegovy, have far exceeded market expectations. The drug, which launched in January, has rapidly become the most successful obesity treatment debut in the United States, with over two million prescriptions written and weekly figures now exceeding 200,000.
Strong Financial Performance
According to the company's latest quarterly report, Wegovy generated 2.26 billion Danish krone (approximately £261 million) in sales during the three months ending 31 March. This figure surpassed analyst predictions and helped boost investor confidence. Despite a slight decline in adjusted net sales and operating profit for the overall quarter, Novo Nordisk has raised its 2026 guidance for both adjusted sales and operating profit, citing the strong performance of Wegovy as a key driver.
Market Impact and Competition
The announcement sent shares in the Copenhagen-based company higher, as the pill directly challenges rival Eli Lilly's Mounjaro, another GLP-1 receptor agonist used for weight management. Wegovy's rapid uptake underscores the immense demand for effective obesity treatments, with analysts noting that the market for such drugs is expanding rapidly. Novo Nordisk's decision to raise its full-year outlook reflects confidence in continued strong sales momentum.
The company's stock price rose by over 5% in early trading following the news, with investors responding positively to the upbeat sales figures and upgraded forecasts. The success of Wegovy is seen as a major milestone for Novo Nordisk, which has been investing heavily in its obesity drug pipeline.
